Clinical Trials on Genomic Instability in Japan

Total 472 results

Amicus Therapeutics

Completed

A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

Fabry Disease

Japan, Taiwan, Turkey, United States, Brazil
Novartis Gene Therapies
PRA Health Sciences

Completed

Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

Spinal Muscular Atrophy Type I

Korea, Republic of, Taiwan, Japan
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Mylan Inc.

Completed

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Digestive System Diseases | Pancreatic Diseases | Cystic Fibrosis | Exocrine Pancreatic Insufficiency

Japan
Bayer

Completed

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Japan
Novo Nordisk A/S

Completed

Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)

Noonan Syndrome | Genetic Disorder

Japan
Novartis Pharmaceuticals

Terminated

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

Sickle Cell Disease

Bahrain, Kuwait, Qatar, Saudi Arabia
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-01)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) (EMPIRE-02)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Haemophilia A

Japan
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Novo Nordisk A/S

Enrolling by invitation

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Haemophilia B

Japan, Denmark
Translational Research Center for Medical Innovation...

Terminated

Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M

Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV) | Neutral Lipid Storage Disease With Myopathy (NLSD-M)

Italy, Japan
Takeda

Active, not recruiting

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Alagille Syndrome (ALGS)

Japan
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Novo Nordisk A/S

Completed

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Noonan Syndrome | Genetic Disorder

Japan
Takeda

Completed

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Hereditary Angioedema

Japan
AstraZeneca
Ardea Biosciences, Inc.

Completed

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Gout and Hyperuricemia

Japan
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

Chronic Myelogenous Leukemia

Japan
Chugai Pharmaceutical

Not yet recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS) | Immune Thrombocytopenia (ITP) | Dermatomyositis (DM) | Bullous Pemphigoid (BP) | Behçet's Syndrome (BS) | Immune-mediated Necrotizing Myopathy (IMNM)

United States, Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in Japanese Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Ministry of Health, Labour and Welfare, Japan

Unknown

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Kidney, Polycystic, Autosomal Dominant

Japan
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
Boston University
National Institute of Neurological Disorders and Stroke (NINDS); Food and Drug...

Completed

The Effect of Diflunisal on Familial Amyloidosis

Familial Amyloid Polyneuropathy | Familial Amyloidosis

United States, Italy, Japan, Sweden, United Kingdom
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Shire

Completed

Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) (IDEAMLD)

Metachromatic Leukodystrophy (MLD)

Australia, Denmark, Japan, France, Germany
Shire

Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)

Skin Diseases | Skin Diseases, Genetic | Dermatitis | Eczema | Dermatitis, Atopic

Japan
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (ECZTRA 8)

Atopic Dermatitis

Japan
National Hospital Organization Nagoya Medical Center

Recruiting

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Acute Lymphoblastic Leukemia | Down Syndrome | Childhood Cancer

Taiwan, Thailand, Hong Kong, Singapore, Malaysia, Japan
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
Amicus Therapeutics

Recruiting

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Fabry Disease

Spain, United States, Japan, Australia, France, Portugal
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia

XLH

Japan, Korea, Republic of
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
Bristol-Myers Squibb

Completed

A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Myeloid Leukemia, Chronic

Japan
Bioverativ, a Sanofi company

Completed

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Hemophilia A

United States, Japan
Pfizer

Completed

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China, Japan, Korea, Republic of
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Germany, Japan
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Enrolling by invitation

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)

United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
Genzyme, a Sanofi Company

Active, not recruiting

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (LEAP)

Gaucher Disease Type 1 | Gaucher Disease Type 3

Germany, United States, Japan, United Kingdom
Pfizer

Terminated

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Japan, Italy

Clinical Trials on Genomic Instability in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations